Skip to main content
Premium Trial:

Request an Annual Quote

Johns Hopkins, Scripps Research Institute, Competitive Technologies License Biotechnologies

Licensing institution: Johns Hopkins University
Primary inventors: Katharine Whartenby, assistant professor, oncology, JHU; Donald Small, professor, oncology, JHU
Licensee: Xanthus Pharmaceuticals, Cambridge, Mass.
Technology: Xanthus has taken an exclusive worldwide license to a patent estate for treating immune-related disorders by inhibiting the FLT3 tyrosine kinase. In addition, Xanthus and JHU have initiated a research project to assess novel compounds for FLT3 inhibitory activity and the downstream pathways relevant to a range of automimmune diseases.

Licensing institution: Scripps Research Institute
Primary inventor: Joel Gottesfeld, professor, molecular biology, Scripps Research Institute
Licensee: Repligen, Waltham, Mass.
Technology: Repligen has taken an exclusive worldwide license to IP covering compounds that may have utility in Friedreich’s ataxia, an inherited neurodegenerative disease in which low levels of the protein frataxin result in progressive damage to the nervous system and loss of muscle function.

Licensing institution: Competitive Technologies
Primary inventor: Harley Rotbart, professor, pediatrics and microbiology, University of Colorado Health Sciences Center
Licensee: Focus Diagnostics, Cypress, Calif.
Technology: Focus Diagnostics will be producing enterovirus assay kits under a recently expanded license granted to it for use of patented technology for the rapid assay of human enteroviruses. The technology was developed by Harley Rothbart at UC, a Competitive Technologies client.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.